Cargando…

Can’t Dissolve Me Now: A COVID-19 Provoked Venous Thromboembolism Breaks Through Apixaban: Case Report

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is a multisystem process with a growing evidence of its endotheliopathy effects, with subsequent hypercoagulability states. CASE REPORT: WWe present an emergency department case of a COVID-19-provoked deep venous thrombosis and pulmonary embolism wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arena, Alexander W., Hussein, Ahmad, Kurkowski, Ellen J., Kulkarni, Miriam L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	University of California Irvine, Department of Emergency Medicine publishing Western Journal of Emergency Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143841/ https://www.ncbi.nlm.nih.gov/pubmed/34437005 http://dx.doi.org/10.5811/cpcem.2021.3.50505

Ejemplares similares

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism
por: Puhr, Hannah C., et al.
Publicado: (2019)

Omalizumab as a Provoking Factor for Venous Thromboembolism
por: Oblitas, Crhistian-Mario, et al.
Publicado: (2019)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Cocaine: A Provoking Risk Factor in Venous Thromboembolism
por: Griffin, Daniel, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation
por: Jethwa, Trisha E, et al.
Publicado: (2022)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
por: Liu, Xianchen, et al.
Publicado: (2015)

Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?
por: Fabbian, Fabio, et al.
Publicado: (2016)

Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
por: Al Yami, Majed S., et al.
Publicado: (2023)

You can't talk to me that way!: stopping toxic language in the workplace
por: Bell, Arthur H
Publicado: (2005)

If You Can't Measure It, You Can't Manage It
por: Peccoud, Jean
Publicado: (2014)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

You Can't See Me: Anonymizing Graphs Using the Szemerédi Regularity Lemma
por: Foffano, Daniele, et al.
Publicado: (2019)

Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real‐World Practice Mirrors Guideline Recommendations
por: Joyce, Elizabeth, et al.
Publicado: (2022)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2o1p6gnoqjkvv2v0dcieeal837